Advertisement

Topics

PubMed Journals Articles About "Takeda TiGenix Announce Publication Lancet Week Results Phase" RSS

22:50 EDT 17th August 2018 | BioPortfolio

Takeda TiGenix Announce Publication Lancet Week Results Phase PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Takeda TiGenix Announce Publication Lancet Week Results Phase articles that have been published worldwide.

More Information about "Takeda TiGenix Announce Publication Lancet Week Results Phase" on BioPortfolio

We have published hundreds of Takeda TiGenix Announce Publication Lancet Week Results Phase news stories on BioPortfolio along with dozens of Takeda TiGenix Announce Publication Lancet Week Results Phase Clinical Trials and PubMed Articles about Takeda TiGenix Announce Publication Lancet Week Results Phase for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda TiGenix Announce Publication Lancet Week Results Phase Companies in our database. You can also find out about relevant Takeda TiGenix Announce Publication Lancet Week Results Phase Drugs and Medications on this site too.

Showing "Takeda TiGenix Announce Publication Lancet Week Results Phase" PubMed Articles 1–25 of 48,000+

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results.

The 24-week equivalent efficacy and comparable safety results of SB5 and reference adalimumab (ADA) from the phase 3 randomized study in patients with moderate to severe rheumatoid arthritis (RA) have been reported previously. This transition study evaluated patients who switched from ADA to SB5 or continued on SB5 or ADA up to 52 weeks.


Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial.

Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.

This phase III clinical trial compared the immunogenicity and safety of a purified chick-embryo cell rabies vaccine (PCECV) administered according to a shortened post-exposure prophylaxis (PEP) 4-site/1-week intradermal regimen, compared with the currently recommended 2-site/Thai Red Cross (TRC).


Digestive Disease Week 2018.

Measurement of three-dimensional wavefronts using the Ichikawa-Lohmann-Takeda solution to the irradiance transport equation.

In this paper, we use the irradiance transport equation and the Fourier transform-based experimental solution given by Ichikawa-Lohmann-Takeda. We analyze experimental factors such as the digital filter, the introduced error for the rotation and period of the Ronchi ruling, and a new method is demonstrated for the measurement of 3D wavefront information.

Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL. METHODS: Patients with moderate plaque ps...

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn's disease. Here we aimed to assess the efficacy and safety of extended intravenous induction and subcutaneous maintenance therapy with risankizumab.

Initiation and publication time-lags of treatment trials for Ebola virus disease.

Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, non-inferiority trial.

Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated non-inferior efficacy and similar safety to raltegravir 400mg BID at Week 48 of the ONCEMRK trial. Here we report the Week 96 results from this study.

Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial.

Neutralizing interleukin (IL)-17F in addition to IL-17A may provide a more complete and specific approach to inhibiting inflammation.

Correction to Lancet Oncol 2017; 18: 1565-66.

Correction to Lancet Oncol 2017; 18: 1493-501.

Correction to Lancet Respir Med 2018; 6: e2.

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Millennium Pharmaceuticals, and Onyx Pharmaceuticals; and is a member of advisory boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte, Kite, Legend Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals.

Accelerate progress-sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission.

Germany's delayed coal phase-out and respiratory health.

Stereotactic body radiation therapy (SBRT) for central early stage non-small cell lung cancer: results of a prospective phase I/II trial.

We report results from a prospective phase I/II trial for patients with centrally-located, early-stage non-small cell lung cancer (NSCLC) receiving stereotactic body radiation therapy (SBRT).

An Investigation Into the Effects of Excluding the Catch Phase of the Power Clean on Force-Time Characteristics During Isometric and Dynamic Tasks: An Intervention Study.

Comfort, P, Dos'Santos, T, Thomas, C, McMahon, JJ, and Suchomel, TJ. An investigation into the effects of excluding the catch phase of the power clean on force-time characteristics during isometric and dynamic tasks: an intervention study. J Strength Cond Res XX(X): 000-000, 2018-The aims of this study were to compare the effects of the exclusion or inclusion of the catch phase during power clean (PC) derivatives on force-time characteristics during isometric and dynamic tasks, after two 4-week mesocycles o...

A randomized, multicentre phase III study of three different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of three different doses (0.5, 1.0 and 2.0 g/kg) of IVIg 10% (panzyga®) administered every 3 weeks for 24 weeks. The primary efficacy endpoint is the rate of treatment response, defined as a decrease in adjusted Inflammatory Neuropathy Cause and T...

Twelve-week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.

The need for all-oral HCV treatments with higher response rates, improved tolerability and lower pill burden compared to interferon-inclusive regimen has led to the development of new direct-acting antiviral agents (DAAs). Ravidasvir (RDV) is a second-generation, pan-genotypic NS5A inhibitor with high barrier to resistance. The aim of this phase 2 study (EVERST study) was to assess the efficacy and safety of interferon-free, 12-week RDV plus ritonavir-boosted danoprevir (DNVr) and ribavirin (RBV) regimen fo...

Effects of Far-Infrared Emitting Ceramic Materials on Recovery During 2-Week Preseason of Elite Futsal Players.

Nunes, RFH, Cidral-Filho, FJ, Flores, LJF, Nakamura, FY, Rodriguez, HFM, Bobinski, F, De Sousa, A, Petronilho, F, Danielski, LG, Martins, MM, Martins, DF, and Guglielmo, LGA. Effects of far-infrared emitting ceramic materials on recovery during 2-week preseason of elite futsal players. J Strength Cond Res XX(X): 000-000, 2018-We investigated the effects of far-infrared emitting ceramic materials (cFIR) during overnight sleep on neuromuscular, biochemical and perceptual markers in futsal players. Twenty athl...

Absolute sensitivity of phase measurement in an SU(1,1) type interferometer.

Absolute sensitivity is measured for the phase measurement in an SU(1,1) type interferometer, and the results are compared to that of a Mach-Zehnder interferometer operated under the condition of the same intra-interferometer intensity. The interferometer is phase locked to a point with the largest quantum noise cancellation, and a simulated phase modulation is added in one arm of the SU(1,1) interferometer. Both the signal and noise level are estimated at the same frequency range, and we obtained 3 dB imp...

Correction to Lancet Glob Health 2018; 6: e180-92.

Correction to Lancet Planet Health 2017; 1: e277-88.

Correction to Lancet Planet Health 2017; 1: e289-97.


Advertisement
Quick Search
Advertisement
Advertisement